In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.
In patients with COPD, tiotropium/olodaterol was associated with a lower risk for escalation to triple therapy or the development of adverse outcomes compared with LABA/ICS.